Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
SK Eternix Co Ltd
KRX:475150
|
KR |
|
United Inc
TSE:2497
|
JP |
|
Medi Lifestyle Ltd
SGX:5TN
|
SG |
|
European Wax Center Inc
NASDAQ:EWCZ
|
US |
|
Fuso Chemical Co Ltd
TSE:4368
|
JP |
|
Barcino Property SOCIMI SA
MAD:YBAR
|
ES |
|
Banco do Estado do Rio Grande do Sul SA
BOVESPA:BRSR6
|
BR |
|
P
|
Prudent Corporate Advisory Services Ltd
NSE:PRUDENT
|
IN |
|
Henry Schein Inc
NASDAQ:HSIC
|
US |
|
Crown Electrokinetics Corp.
NASDAQ:CRKN
|
US |
|
Rayonier Inc
NYSE:RYN
|
US |
Molecular Partners AG
Total Assets
Molecular Partners AG
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Total Assets
CHf102.1m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Assets
$2.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
30%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Assets
CHf282m
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Assets
CHf465.9m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Assets
CHf110m
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Assets
CHf48m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Total Assets?
Total Assets
102.1m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Total Assets amounts to 102.1m CHF.
What is Molecular Partners AG's Total Assets growth rate?
Total Assets CAGR 5Y
-11%
Over the last year, the Total Assets growth was -36%. The average annual Total Assets growth rates for Molecular Partners AG have been -27% over the past three years , -11% over the past five years .
